New approaches to address dyslipidemia

Area of Science:

• Cardiovascular Medicine
• Pharmacology
• Lipid Metabolism

Background:

• Current lipid-lowering therapies like statins, ezetimibe, and PCSK9 inhibitors are effective but have limitations.
• Some patients exhibit insufficient response or intolerance to existing treatments.
• Specific dyslipidemias, including homozygous familial hypercholesterolemia and elevated lipoprotein(a), remain challenging to manage.

Purpose of the Study:

• To review emerging drug developments for lipid management.
• To address unmet needs in treating patients with refractory or complex dyslipidemias.
• To explore novel therapeutic strategies beyond current standards of care.

Main Methods:

• Focus on novel therapeutic modalities including antibodies, antisense oligonucleotides, and small molecules.
• Evaluation of drugs targeting diverse pathways in lipid metabolism.
• Review of ongoing clinical trials assessing efficacy and safety.

Main Results:

• Promising candidates demonstrate reductions in LDL-cholesterol, non-HDL-cholesterol, triglycerides, and lipoprotein(a).
• These agents show potential for patients with limited treatment options.
• Various drugs are progressing through different phases of clinical development.

Conclusions:

• Several new lipid-lowering drugs exhibit promising profiles for managing dyslipidemias.
• Further phase 3 and outcome trials are essential to confirm clinical utility.
• These novel therapies are unlikely to replace statins and ezetimibe as first-line treatments.